IDYAIDEAYA BiosciencesSigning up patients
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Uveal Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 520 (planned)
- Started
- Jan 25, 2026
- Main results expected
- Oct 2030
- Fully finished
- Mar 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: To demonstrate that the proportion of subjects with vision loss is lower for subjects in the Treatment Arm vs the Control Arm
Measured over: Approximately 3 years
Cohort 2: To demonstrate the ability to salvage the eye and prevent enucleation in the Treatment Arm
Measured over: Approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07015190 · record last updated 2026-05-06 · checked 2026-11-09 15:36 UTC